Lowest Price Guaranteed
Pages
450
Last Updated
May 2026
View Count
28485
1. PREFACE
1.1. Market Overview
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on Market
3.2.2.4. Strategies For Mitigating Foreign Exchange Risk
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Targeted Protein Degradation
5.2.1. Historical Evolution of Targeted Protein Degraders
5.3. Targeted Protein Degrader Pathway
5.4. Types of Protein Degraders
5.4.1. Proteolysis Targeting Chimeras (PROTACs)
5.4.2. Endosome Targeting Chimeras (ENDTACs)
5.4.3. Photochemically Targeted Chimeras (PHOTACs)
5.4.4. Hydrophobic Tags
5.4.5. Immunomodulatory Imide Drugs (IMiDs)
5.4.6. Molecular Glues
5.4.7. Selective Hormone Receptor Degraders (SHRDs)
5.4.8. Specific and Nongenetic inhibitor-of-apoptosis proteins (IAP)- Dependent Protein Erasers (SNIPERs)
5.4.9. DUB Inhibitors
5.4.10. Other Protein Degraders
5.5. Targeted Therapeutic Areas
5.6. Benefits and Challenges Associated with Targeted Protein Degradation
5.7. Future Perspectives
6. MARKET LANDSCAPE: TARGETED PROTEIN DEGRADATION THERAPIES
6.1. Chapter Overview
6.2. Targeted Protein Degradation Therapies: Overall Market Landscape
6.2.1. Analysis by Stage of Development
6.2.2. Analysis by Type of Degrader
6.2.3. Analysis by Biological Target
6.2.4. Analysis by Target Enzyme
6.2.5. Analysis by Target Indication
6.2.6. Analysis by Therapeutic Area
6.3. Targeted Protein Degradation Therapy Developers: Overall Market Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters (Region)
6.3.4. Analysis by Year of Establishment and Location of Headquarters (Region)
6.3.5. Analysis by Company Size and Location of Headquarters (Region)
6.3.6. Most Active Developers: Distribution by Number of Therapies and Stage of Development
7. MARKET LANDSCAPE: TARGETED PROTEIN DEGRADATION TECHNOLOGIES
7.1. Chapter Overview
7.2. Targeted Protein Degradation Technologies: Overall Market Landscape
7.2.1. Analysis by Type of Degrader Developed
7.2.2. Analysis by Protein Degradation Pathway
7.2.3. Analysis by Site of Degraded Protein
7.2.4. Analysis by Therapeutic Area
7.2.5. Analysis by Discovery Step Supported
7.2.6. Analysis by Availability of Computational Modeling Ability
7.2.7. Analysis by Year of Establishment
7.2.8. Analysis by Company Size
7.2.9. Analysis by Location of Headquarters (Region)
7.2.10. Analysis by Year of Establishment and Location of Headquarters (Region)
7.2.11. Analysis by Company Size and Location of Headquarters (Region)
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Detailed Company Profiles of Prominent Players
8.2.1. Arvinas
8.2.1.1. Company Overview
8.2.1.2. Financial Information
8.2.1.3. Technology Portfolio
8.2.1.4. Pipeline Overview
8.2.1.5. Recent Developments and Future Outlook
8.2.2. Bristol-Myers Squibb
8.2.2.1. Company Overview
8.2.2.2. Financial Information
8.2.2.3. Technology Portfolio
8.2.2.4. Pipeline Overview
8.2.2.5. Recent Developments and Future Outlook
8.2.3. C4 Therapeutics
8.2.3.1. Company Overview
8.2.3.2. Financial Information
8.2.3.3. Technology Portfolio
8.2.3.4. Pipeline Overview
8.2.3.5. Recent Developments and Future Outlook
8.2.4. Loxo Oncology
8.2.4.1. Company Overview
8.2.4.2. Pipeline Overview
8.2.4.3. Recent Developments and Future Outlook
8.2.5. Olema Oncology
8.2.5.1. Company Overview
8.2.5.2. Pipeline Overview
8.2.5.3. Recent Developments and Future Outlook
8.2.6. Radius Health
8.2.6.1. Company Overview
8.2.6.2. Financial Information
8.2.6.3. Pipeline Overview
8.2.6.4. Recent Developments and Future Outlook
8.2.7. AstraZeneca
8.2.7.1. Company Overview
8.2.7.2. Financial Information
8.2.7.3. Pipeline Overview
8.2.7.4. Recent Developments and Future Outlook
8.2.8. Roche
8.2.8.1. Company Overview
8.2.8.2. Financial Information
8.2.8.3. Pipeline Overview
8.2.8.4. Recent Developments and Future Outlook
8.3. Short Profiles of Other Prominent Players
8.3.1. BeiGene
8.3.1.1. Company Overview
8.3.1.2. Pipeline Overview
8.3.2. InnoCare Pharma
8.3.2.1. Company Overview
8.3.2.2. Technology Portfolio
8.3.2.3. Pipeline Overview
8.3.3. Kangpu Biopharmaceuticals
8.3.3.1. Company Overview
8.3.3.2. Technology Portfolio
8.3.3.3. Pipeline Overview
8.3.4. Kintor Pharmaceuticals
8.3.4.1. Company Overview
8.3.4.2. Technology Portfolio
8.3.4.3. Pipeline Overview
8.3.5. Medivir
8.3.5.1. Company Overview
8.3.5.2. Technology Portfolio
8.3.5.3. Pipeline Overview
8.3.6. Monte Rosa Therapeutics
8.3.6.1. Company Overview
8.3.6.2. Technology Portfolio
8.3.6.3. Pipeline Overview
8.3.7. Ranok Therapeutics
8.3.7.1. Company Overview
8.3.7.2. Technology Portfolio
8.3.7.3. Pipeline Overview
8.3.8. Sanofi
8.3.8.1. Company Overview
8.3.8.2. Pipeline Overview
8.3.9. Zentalis Pharmaceuticals
8.3.9.1. Company Overview
8.3.9.2. Technology Portfolio
8.3.9.3. Pipeline Overview
8.3.10. Eisai Therapeutics
8.3.10.1. Company Overview
8.3.10.2. Pipeline Overview
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Targeted Protein Degradation: Clinical Trial Analysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
9.3.3. Analysis by Trial Phase
9.3.4. Analysis of Number of Patients Enrolled by Trial Phase
9.3.5. Analysis by Trial Registration Year and Trial Phase
9.3.6. Analysis by Trial Status
9.3.7. Analysis by Patient Gender
9.3.8. Analysis by Target Indication
9.3.9. Analysis by Study Design
9.3.9.1. Analysis by Type of Trial Masking
9.3.9.2. Analysis by Type of Intervention Model
9.3.9.3. Analysis by Trial Purpose
9.3.9.4. Analysis by Design Allocation
9.3.10. Most Active Sponsor / Collaborator: Analysis by Number of Registered Trials
9.3.10.1. Analysis by Leading Industry Players
9.3.10.2. Analysis by Leading Non-Industry Players
9.3.11. Analysis by Geography
9.3.11.1. Analysis of Clinical Trials by Trial Status and Geography
9.3.11.2. Analysis of Patients Enrolled by Trial Status and Geography
10. GRANTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Targeted Protein Degradation: Grants Analysis
10.3.1. Analysis by Year of Grant Award
10.3.2. Analysis by Amount Awarded
10.3.3. Analysis by Funding Institute Center
10.3.4. Analysis by Support Period
10.3.5. Analysis by Funding Institute Center and Support Period
10.3.6. Analysis by Type of Grant Application
10.3.7. Analysis by Purpose of Grant Award
10.3.8. Analysis by Activity Code
10.3.9. Analysis by Study Section Involved
10.3.10. Most Popular NIH Departments: Analysis by Number of Grants
10.3.11. Prominent Program Officers: Analysis by Number of Grants
10.3.12. Popular Recipient Organizations: Analysis by Number of Grants
10.3.13. Popular Recipient Organizations: Analysis by Grant Amount
10.3.14. Popular Recipient Organizations: Analysis by States in the US
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Targeted Protein Degradation: Patents Analysis
11.3.1. Analysis by Patent Publication Year
11.3.2. Analysis by Patent Application Year
11.3.3. Analysis of Granted Patents and Patent Applications by Publication Year
11.3.4. Analysis by Patent Jurisdiction
11.3.5. Analysis by CPC Symbols
11.3.6. Analysis by Type of Applicant
11.3.7. Leading Industry Players: Analysis by Number of Patents
11.3.8. Leading Non-Industry Players: Analysis by Number of Patents
11.3.9. Leading Patent Assignees: Analysis by Number of Patents
11.4. Patent Benchmarking Analysis
11.4.1. Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
11.5. Patent Valuation
11.6. Leading Patents by Number of Citations
12. PUBLICATION ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Targeted Protein Degradation: Publication Analysis
12.3.1. Analysis by Year of Publication
12.3.2. Analysis by Type of Publication
12.3.3. Key Journals: Analysis by Number of Publications
12.3.4. Key Journals: Analysis by Journal Impact Factor
12.3.5. Most Active Publisher: Analysis by Number of Publications
12.3.6. Most Active Copyright Holder: Analysis by Number of Publications
12.3.7. Analysis by Emerging Focus Area
12.3.8. Analysis by Therapeutic Area
12.3.9. Analysis by Geography
13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models
13.3. Targeted Protein Degradation: Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year and Type of Partnership
13.3.4. Analysis by Type of Partner
13.3.5. Analysis by Type of Degrader
13.3.6. Most Active Players: Analysis by Number of Partnerships
13.4. Analysis by Geography
13.4.1. Local and International Agreements
13.4.2. Intercontinental and Intracontinental Agreements
14. FUNDING AND INVESTMENTS
14.1. Chapter Overview
14.2. Funding Models
14.3. Targeted Protein Degradation: Funding and Investments
14.3.1. Analysis by Year of Funding
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Amount Invested and Type of Funding
14.3.5. Analysis of Amount Invested by Year and Type of Funding
14.3.6. Analysis by Geography
14.3.7. Most Active Players
14.3.7.1. Analysis by Number of Funding Instances
14.3.7.2. Analysis by Amount Invested
14.3.8. Leading Investors: Analysis by Number of Funding Instances
14.4. Concluding Remarks
15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
15.1. Chapter Overview
15.2. Market Drivers
15.3. Market Restraints
15.4. Market Opportunities
15.5. Market Challenges
15.6. Conclusion
16. GLOBAL TARGETED PROTEIN DEGRADATION THERAPIES MARKET
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Global Targeted Protein Degradation Therapies Market, Forecasted Estimates (2024-2035)
16.3.1. Scenario Analysis
16.3.1.1. Conservative Scenario
16.3.1.2. Optimistic Scenario
16.4. Key Market Segmentations
17. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY TYPE OF DEGRADER
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Targeted Protein Degradation Therapies Market: Distribution by Type of Degrader, 2024 and 2035
17.3.1. Targeted Protein Degradation Therapies Market for SERDs: Forecasted Estimates (2024-2035)
17.3.2. Targeted Protein Degradation Therapies Market for PROTACs: Forecasted Estimates (2024-2035)
17.3.3. Targeted Protein Degradation Therapies Market for Molecular Glues: Forecasted Estimates (2024-2035)
17.4. Data Triangulation and Validation
18. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY TARGET INDICATION
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Targeted Protein Degradation Therapies Market: Distribution by Target Indication, 2024 and 2035
18.3.1. Targeted Protein Degradation Therapies Market for Breast Cancer: Forecasted Estimates (2024-2035)
18.3.2. Targeted Protein Degradation Therapies Market for Multiple Myeloma: Forecasted Estimates (2024-2035)
18.4. Data Triangulation and Validation
19. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, BY KEY GEOGRAPHICAL REGIONS
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Targeted Protein Degradation Therapies Market: Distribution by Key Geographical Regions, 2024 and 2035
19.3.1. Targeted Protein Degradation Therapies Market in North America: Forecasted Estimates (2024-2035)
19.3.1.1. Targeted Protein Degradation Therapies Market in US: Forecasted Estimates (2024-2035)
19.3.1.2. Targeted Protein Degradation Therapies Market in Canada: Forecasted Estimates (2024-2035)
19.3.2. Targeted Protein Degradation Therapies Market in Europe: Forecasted Estimates (2024-2035)
19.3.2.1. Targeted Protein Degradation Therapies Market in UK: Forecasted Estimates (2024-2035)
19.3.2.2. Targeted Protein Degradation Therapies Market in Germany: Forecasted Estimates (2024-2035)
19.3.2.3. Targeted Protein Degradation Therapies Market in France: Forecasted Estimates (2024-2035)
19.3.2.4. Targeted Protein Degradation Therapies Market in Italy: Forecasted Estimates (2024-2035)
19.3.2.5. Targeted Protein Degradation Therapies Market in Spain: Forecasted Estimates (2024-2035)
19.3.3. Targeted Protein Degradation Therapies Market in Asia-Pacific: Forecasted Estimates (2024-2035)
19.3.3.1. Targeted Protein Degradation Therapies Market in China: Forecasted Estimates (2026-2035)
19.3.3.2. Targeted Protein Degradation Therapies Market in South Korea: Forecasted Estimates (2026-2035)
19.3.3.3. Targeted Protein Degradation Therapies Market in India: Forecasted Estimates (2027-2035)
19.3.3.4. Targeted Protein Degradation Therapies Market in Japan: Forecasted Estimates (2027-2035)
19.3.3.5. Targeted Protein Degradation Therapies Market in Australia: Forecasted Estimates (2027-2035)
19.3.4. Targeted Protein Degradation Therapies Market in Rest of the World: Forecasted Estimates (2026-2035)
19.3.4.1. Targeted Protein Degradation Therapies Market in Brazil: Forecasted Estimates (2026-2035)
19.3.4.2. Targeted Protein Degradation Therapies Market in Israel: Forecasted Estimates (2027-2035)
19.5. Data Triangulation and Validation
20. TARGETED PROTEIN DEGRADATION THERAPIES MARKET, SALES FORECAST OF DRUGS
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Commercialized Targeted Protein Degradation Therapies Market: Sales Forecast
20.3.1. RAD1901 / Elacestrant / Orserdu Sales Forecast
20.4. Phase III Targeted Protein Degradation Therapies Market: Sales Forecast
20.4.1. Vepdegestrant / ARV-471 Sales Forecast
20.4.2. Camizestrant / AZD9833 Sales Forecast
20.4.3. CC-92480 / BMS-986348 / Mezigdomide Sales Forecast
20.4.4. LY3484356 / Imlunestrant Sales Forecast
20.4.5. OP-1250 / OP-1250-301 / Palazestrant Sales Forecast
20.5. Data Triangulation and Validation
21. GLOBAL TARGETED PROTEIN DEGRADATION TECHNOLOGIES MARKET
21.1. Chapter Overview
21.2. Key Assumptions
21.3. Forecast Methodology
21.4. Global Targeted Protein Degradation Technologies Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
21.4.1. Scenario Analysis
21.4.1.1. Conservative Scenario
21.4.1.2. Optimistic Scenario
21.5. Targeted Protein Degradation Technologies Market: Distribution by Type of Payment Model Employed, 2018, 2024 and 2035
21.5.1. Targeted Protein Degradation Technologies Market for Upfront Payments: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
21.5.2. Targeted Protein Degradation Technologies Market for Milestone Payments: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
21.6. Data Triangulation and Validation
22. EXECUTIVE INSIGHTS
22.1. Chapter Overview
22.2. GlycoEra
22.2.1. Company Snapshot
22.2.2. Interview Transcript: Ganesh Kaundinya, Chief Executive Officer and President
22.3. Polyprox Therapeutics
22.3.1. Company Snapshot
22.3.2. Interview Transcript: Laura Itzhaki, Chief Scientific Officer and Founder
22.4. Xios Therapeutics
22.4.1. Company Snapshot
22.4.2. Interview Transcript: Louise Bergeron, Former Chief Scientific Officer and Former Vice President, Research
22.5. Mission Therapeutics
22.5.1. Company Snapshot
22.5.2. Interview Transcript: Paul Wallace, Former Chief Business Officer
22.6. Ubiquigent
22.6.1. Company Snapshot
22.6.2. Interview Transcript: Jason Brown, Former Scientific and Business Development Director
22.7. Almac Discovery
22.7.1. Company Snapshot
22.7.2. Interview Transcript: Martin Wales, Former Vice President, Business Development and Licensing and Gerald Gavory, Former Vice President, Biology
22.8. University of Delaware
22.8.1. Company Snapshot
22.8.2. Interview Transcript: Zhihao Zhuang (Professor)
22.9 Francis Crick Institute
22.9.1. Company Snapshot
22.9.2. Interview Transcript: Katrin Rittinger (Group Leader)
22.10 Anonymous
22.10.1. Interview Transcript: Chief Scientific Officer
22.11 Anonymous
22.11.1. Interview Transcript: Director of Oncology Research
23. CONCLUSION
24. APPENDIX 1: TABULATED DATA
25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
26. APPENDIX 3: LIST OF FUNDING AND INVESTMENTS
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Targeted Protein Degradation Therapies Market Landscape
Figure 4.2 Executive Summary: Targeted Protein Degradation Technologies Market Landscape
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Grants Analysis
Figure 4.5 Executive Summary: Patent Analysis
Figure 4.6 Executive Summary: Publication Analysis
Figure 4.7 Executive Summary: Partnerships and Collaborations
Figure 4.8 Executive Summary: Funding and Investments
Figure 4.9 Executive Summary: Therapies Market Forecast and Opportunity Analysis
Figure 4.10 Executive Summary: Technologies Market Forecast and Opportunity Analysis
Figure 5.1 Timeline of Induced Protein Degradation Field
Figure 5.2 Ubiquitin-Proteasome System Pathway
Figure 5.3 Types of Protein Degraders
Figure 5.4 Mechanism of Action of PROTAC
Figure 5.5 Advantages of PROTACs
Figure 5.6 Mechanism of Action of ENDTAC
Figure 5.7 Mechanism of Action of PHOTAC
Figure 5.8 Mechanism of Action of Hydrophobic Tag
Figure 5.9 Mechanism of Action of IMiD
Figure 5.10 Mechanism of Action of Molecular Glue
Figure 5.11 Mechanism of Action of SERD
Figure 5.12 Mechanism of Action of SNIPER
Figure 5.13 Protein Degradation: Targeted Therapeutic Areas
Figure 6.1 Targeted Protein Degradation Therapies: Distribution by Stage of Development
Figure 6.2 Targeted Protein Degradation Technologies: Distribution by Type of Degrader
Figure 6.3 Targeted Protein Degradation Therapies: Distribution by Biological Target
Figure 6.4 Targeted Protein Degradation Therapies: Distribution by Target Enzyme
Figure 6.5 Targeted Protein Degradation Therapies: Distribution by Target Indication
Figure 6.6 Targeted Protein Degradation Therapies: Distribution by Therapeutic Area
Figure 6.7 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment
Figure 6.8 Targeted Protein Degradation Therapy Developers: Distribution by Company Size
Figure 6.9 Targeted Protein Degradation Therapy Developers: Distribution by Location of Headquarters (Region)
Figure 6.10 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment and Location of Headquarters (Region)
Figure 6.11 Targeted Protein Degradation Therapy Developers: Distribution by Company Size and Location of Headquarters (Region)
Figure 6.12 Most Active Developers: Distribution by Number of Therapies and Stage of Development
Figure 7.1 Targeted Protein Degradation Technologies: Distribution by Type of Degrader Developed
Figure 7.2 Targeted Protein Degradation Technologies: Distribution by Protein Degradation Pathway
Figure 7.3 Targeted Protein Degradation Technologies: Distribution by Site of Degraded Protein
Figure 7.4 Targeted Protein Degradation Technologies: Distribution by Therapeutic Area
Figure 7.5 Targeted Protein Degradation Technologies: Distribution by Discovery Step Supported
Figure 7.6 Targeted Protein Degradation Technologies: Distribution by Availability of Computational Modeling Ability
Figure 7.7 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment
Figure 7.8 Targeted Protein Degradation Technology Providers: Distribution by Company Size
Figure 7.9 Targeted Protein Degradation Technology Providers: Distribution by Location of Headquarters (Region)
Figure 7.10 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment and Location of Headquarters (Region)
Figure 7.11 Targeted Protein Degradation Technology Providers: Distribution by Company Size and Location of Headquarters (Region)
Figure 8.1 Arvinas: Annual Revenues, FY 2019-FY 2023 (USD Million)
Figure 8.2 Bristol-Myers Squibb: Annual Revenues, FY 2019-FY 2023 (USD Billion)
Figure 8.3 C4 Therapeutics: Annual Revenues, FY 2019-FY 2023 (USD Million)
Figure 8.4 Radius Health: Annual Revenues, FY 2019-Q1 2022 (USD Million)
Figure 8.5 AstraZeneca: Annual Revenues, FY 2019-FY 2023 (USD Billion)
Figure 8.6 Roche: Annual Revenues, FY 2019-FY 2023 (CHF Billion)
Figure 9.1 Clinical Trial Analysis: Cumulative Year-wise Trend, 2019-2023
Figure 9.2 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, 2019-2023
Figure 9.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 9.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 9.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2019–2023
Figure 9.6 Clinical Trial Analysis: Distribution by Trial Status
Figure 9.7 Clinical Trial Analysis: Distribution by Patient Gender
Figure 9.8 Clinical Trial Analysis: Distribution by Target Indication
Figure 9.9 Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 9.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 9.11 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 9.12 Clinical Trial Analysis: Distribution by Design Allocation
Figure 9.13 Leading Industry Players: Distribution by Number of Registered Trials
Figure 9.14 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 9.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 9.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Figure 10.1 Grants Analysis: Cumulative Year-wise Trend, 2019-2023
Figure 10.2 Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
Figure 10.3 Grants Analysis: Distribution by Funding Institute Center
Figure 10.4 Grants Analysis: Distribution by Support Period
Figure 10.5 Grants Analysis: Distribution by Funding Institute Center and Support Period
Figure 10.6 Grants Analysis: Distribution by Type of Grant Application
Figure 10.7 Grants Analysis: Distribution by Purpose of Grant Award
Figure 10.8 Grants Analysis: Distribution by Activity Code (Series)
Figure 10.9 Grants Analysis: Distribution by Activity Code
Figure 10.10 Grants Analysis: Distribution by Study Section Involved
Figure 10.11 Most Popular NIH Departments: Distribution by Number of Grants
Figure 10.12 Prominent Program Officers: Distribution by Number of Grants
Figure 10.13 Popular Recipient Organizations: Distribution by Number of Grants
Figure 10.14 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Figure 10.15 Popular Recipient Organizations: Distribution by States in the US
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Distribution by Patent Publication Year, 2019-2023
Figure 11.3 Patent Analysis: Distribution by Patent Application Year, Pre-2019-2023
Figure 11.4 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2019-2023
Figure 11.5 Patent Analysis: Distribution by Patent Jurisdiction
Figure 11.6 Patent Analysis: Distribution by CPC Symbols
Figure 11.7 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
Figure 11.8 Leading Industry Players: Distribution by Number of Patents
Figure 11.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.10 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 11.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 11.13 Patent Analysis: Distribution by Patent Age
Figure 11.14 Targeted Protein Degradation: Patent Valuation
Figure 12.1 Publication Analysis: Distribution by Year of Publication, 2019-2023
Figure 12.2 Publication Analysis: Distribution by Type of Publication
Figure 12.3 Key Journals: Distribution by Number of Publications
Figure 12.4 Key Journals: Distribution by Journal Impact Factor
Figure 12.5 Most Active Publisher: Distribution by Number of Publications
Figure 12.6 Most Active Copyright Holder: Distribution by Number of Publications
Figure 12.7 Publication Analysis: Emerging Focus Area
Figure 12.8 Publication Analysis: Distribution by Therapeutic Area
Figure 12.9 Publication Analysis: Distribution by Geography
Figure 13.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2016-2024
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2016-2024
Figure 13.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 13.5 Partnerships and Collaborations: Distribution by Type of Degrader
Figure 13.6 Most Active Players: Distribution by Number of Partnerships
Figure 13.7 Partnership and Collaborations: Local and International Agreements
Figure 13.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2014-2024
Figure 14.2 Funding and Investment Analysis: Distribution by Amount Invested, 2014-2024 (USD Million)
Figure 14.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2018-2024
Figure 14.4 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 14.5 Year-wise Distribution of Amount Invested by Type of Funding, 2018-2024
Figure 14.6 Funding and Investment Analysis: Distribution by Geography (Region)
Figure 14.7 Funding and Investment Analysis: Distribution by Geography (Country)
Figure 14.8 Most Active Players: Distribution by Number of Funding Instances
Figure 14.9 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 14.10 Leading Investors: Distribution by Number of Funding Instances
Figure 14.11 Funding and Investment Summary, 2018-2024 (USD Million)
Figure 15.1 Targeted Protein Degradation: Market Drivers
Figure 15.2 Targeted Protein Degradation: Market Restraints
Figure 15.3 Targeted Protein Degradation: Market Opportunities
Figure 15.4 Targeted Protein Degradation: Market Challenges
Figure 16.1 Global Targeted Protein Degradation Therapies Market, 2024-2035 (USD Million)
Figure 16.2 Global Targeted Protein Degradation Therapies Market, 2024-2035: Conservative Scenario (USD Million)
Figure 16.3 Global Targeted Protein Degradation Therapies Market, 2024-2035: Optimistic Scenario (USD Million)
Figure 17.1 Targeted Protein Degradation Therapies Market: Distribution by Type of Degrader, 2024 and 2035
Figure 17.2 Targeted Protein Degradation Therapies Market for SERDs: Forecasted Estimates (2024-2035) (USD Million)
Figure 17.3 Targeted Protein Degradation Therapies Market for PROTACs: Forecasted Estimates (2025-2035) (USD Million)
Figure 17.4 Targeted Protein Degradation Therapies Market for Molecular Glues: Forecasted Estimates (2030-2035) (USD Million)
Figure 18.1 Targeted Protein Degradation Therapies Market: Distribution by Target Indication, 2024 and 2035
Figure 18.2 Targeted Protein Degradation Therapies Market for Breast Cancer: Forecasted Estimates (2024-2035) (USD Million)
Figure 18.3 Targeted Protein Degradation Therapies Market for Multiple Myeloma: Forecasted Estimates (2030-2035) (USD Million)
Figure 19.1 Targeted Protein Degradation Therapies Market: Distribution by Key Geographical Regions, 2024 and 2035 (USD Million)
Figure 19.2 Targeted Protein Degradation Therapies Market in North America: Forecasted Estimates (2024-2035) (USD Million)
Figure 19.3 Targeted Protein Degradation Therapies Market in the US: Forecasted Estimates (2024-2035) (USD Million)
Figure 19.4 Targeted Protein Degradation Therapies Market in Canada: Forecasted Estimates (2024-2035) (USD Million)
Figure 19.5 Targeted Protein Degradation Therapies Market in Europe: Forecasted Estimates (2024-2035) (USD Million)
Figure 19.6 Targeted Protein Degradation Therapies Market in the UK: Forecasted Estimates (2024-2035) (USD Million)
Figure 19.7 Targeted Protein Degradation Therapies Market in Germany: Forecasted Estimates (2024-2035) (USD Million)
Figure 19.8 Targeted Protein Degradation Therapies Market in France: Forecasted Estimates (2024-2035) (USD Million)
Figure 19.9 Targeted Protein Degradation Therapies Market in Spain: Forecasted Estimates (2024-2035) (USD Million)
Figure 19.10 Targeted Protein Degradation Therapies Market in Italy: Forecasted Estimates (2024-2035) (USD Million)
Figure 19.11 Targeted Protein Degradation Therapies Market in Asia-Pacific: Forecasted Estimates (2026-2035) (USD Million)
Figure 19.12 Targeted Protein Degradation Therapies Market in China: Forecasted Estimates (2026-2035) (USD Million)
Figure 19.13 Targeted Protein Degradation Therapies Market in South Korea: Forecasted Estimates (2026-2035) (USD Million)
Figure 19.14 Targeted Protein Degradation Therapies Market in India: Forecasted Estimates (2027-2035) (USD Million)
Figure 19.15 Targeted Protein Degradation Therapies Market in Japan: Forecasted Estimates (2027-2035) (USD Million)
Figure 19.16 Targeted Protein Degradation Therapies Market in Australia: Forecasted Estimates (2027-2035) (USD Million)
Figure 19.17 Targeted Protein Degradation Therapies Market in Rest of the World: Forecasted Estimates (2026-2035) (USD Million)
Figure 19.18 Targeted Protein Degradation Therapies Market in Brazil: Forecasted Estimates (2026-2035) (USD Million)
Figure 19.19 Targeted Protein Degradation Therapies Market in Israel: Forecasted Estimates (2027-2035) (USD Million)
Figure 20.1 Targeted Protein Degradation Therapies Market: RAD1901 / Elacestrant / Orserdu Sales Forecast, 2024-2035 (USD Million)
Figure 20.2 Targeted Protein Degradation Therapies Market: Vepedegestrant / ARV-471 Sales Forecast, 2025-2035 (USD Million)
Figure 20.3 Targeted Protein Degradation Therapies Market: OP-1250 / OP-1250-301 / Palazestrant Sales Forecast, 2027-2035 (USD Million)
Figure 20.4 Targeted Protein Degradation Therapies Market: LY3484356 / Imlunestrant Sales Forecast, 2028-2035 (USD Million)
Figure 20.5 Targeted Protein Degradation Therapies Market: CC-92480 / BMS-986348 / Mezigdomide Sales Forecast, 2030-2035 (USD Million)
Figure 20.6 Targeted Protein Degradation Therapies Market: Camizestrant / AZD9833 Sales Forecast, 2031-2035 (USD Million)
Figure 21.1 Licensing Agreements: Distribution of Financial Components
Figure 21.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 21.3 Global Targeted Protein Degradation Technologies Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.4 Global Targeted Protein Degradation Technologies Market, 2024-2035: Conservative Scenario (USD Million)
Figure 21.5 Global Targeted Protein Degradation Technologies Market, 2024-2035: Optimistic Scenario (USD Million)
Figure 21.6 Targeted Protein Degradation Technologies Market: Distribution by Type of Payment Model Employed, 2018, 2024 and 2035
Figure 21.7 Targeted Protein Degradation Technologies Market for Upfront Payments, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.8 Targeted Protein Degradation Technologies Market for Milestone Payments, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 23.1 Conclusion: Targeted Protein Degradation Therapies Market Landscape
Figure 23.2 Conclusion: Targeted Protein Degradation Technologies Market Landscape
Figure 23.3 Conclusion: Clinical Trial Analysis
Figure 23.4 Conclusion: Grants Analysis
Figure 23.5 Conclusion: Patent Analysis
Figure 23.6 Conclusion: Publication Analysis
Figure 23.7 Conclusion: Partnerships and Collaborations
Figure 23.8 Conclusion: Funding and Investments
Figure 23.9 Conclusion: Therapies Market Forecast and Opportunity Analysis
Figure 23.10 Conclusion: Technologies Market Forecast and Opportunity Analysis
Table 6.1 Targeted Protein Degradation Therapies: Information on Developer, Stage of Development and Type of Degrader
Table 6.2 Targeted Protein Degradation Therapies: Information on Biological Target, Target Enzyme, Target Indication and Therapeutic Area
Table 6.3 Targeted Protein Degradation Therapy Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 7.1 Targeted Protein Degradation Technologies: Information on Type of Degrader Developed, Protein Degradation Pathway and Site of Degraded Protein
Table 7.2 Targeted Protein Degradation Technologies: Information on Therapeutic Area
Table 7.3 Targeted Protein Degradation Technologies: Information on Discovery Step Supported and CADD Ability
Table 7.4 Targeted Protein Degradation Technology Providers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 8.1 List of Targeted Protein Degradation Therapy Developers Profiled
Table 8.2 Arvinas: Company Overview
Table 8.3 Arvinas: Technology Portfolio
Table 8.4 Arvinas: Pipeline Overview
Table 8.5 Arvinas: Recent Developments and Future Outlook
Table 8.6 Bristol-Myers Squibb: Company Overview
Table 8.7 Bristol-Myers Squibb: Technology Portfolio
Table 8.8 Bristol-Myers Squibb: Pipeline Overview
Table 8.9 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 8.10 C4 Therapeutics: Company Overview
Table 8.11 C4 Therapeutics: Technology Portfolio
Table 8.12 C4 Therapeutics: Pipeline Overview
Table 8.13 C4 Therapeutics: Recent Developments and Future Outlook
Table 8.14 Loxo Oncology: Company Overview
Table 8.15 Loxo Oncology: Pipeline Overview
Table 8.16 Olema Oncology: Company Overview
Table 8.17 Olema Oncology: Pipeline Overview
Table 8.18 Olema Oncology: Recent Developments and Future Outlook
Table 8.19 Radius Health: Company Overview
Table 8.20 Radius Health: Pipeline Overview
Table 8.21 Radius Health: Recent Developments and Future Outlook
Table 8.22 AstraZeneca: Company Overview
Table 8.23 AstraZeneca: Pipeline Overview
Table 8.24 Roche: Company Overview
Table 8.25 Roche: Pipeline Overview
Table 8.26 BeiGene: Company Overview
Table 8.27 BeiGene: Pipeline Overview
Table 8.28 InnoCare Pharma: Company Overview
Table 8.29 InnoCare Pharma: Technology Portfolio
Table 8.30 InnoCare Pharma: Pipeline Overview
Table 8.31 Kangpu Biopharmaceuticals: Company Overview
Table 8.32 Kangpu Biopharmaceuticals: Technology Portfolio
Table 8.33 Kangpu Biopharmaceuticals: Pipeline Overview
Table 8.34 Kintor Pharmaceutical: Company Overview
Table 8.35 Kintor Pharmaceutical: Technology Portfolio
Table 8.36 Kintor Pharmaceutical: Pipeline Overview
Table 8.37 Medivir: Company Overview
Table 8.38 Medivir: Technology Portfolio
Table 8.39 Medivir: Pipeline Overview
Table 8.40 Monte Rosa Therapeutics: Company Overview
Table 8.41 Monte Rosa Therapeutics: Technology Portfolio
Table 8.42 Monte Rosa Therapeutics: Pipeline Overview
Table 8.43 Ranok Therapeutics: Company Overview
Table 8.44 Ranok Therapeutics: Technology Portfolio
Table 8.45 Ranok Therapeutics: Pipeline Overview
Table 8.46 Sanofi: Company Overview
Table 8.47 Sanofi: Pipeline Overview
Table 8.48 Zentalis Pharmaceuticals: Company Overview
Table 8.49 Zentalis Pharmaceuticals: Technology Portfolio
Table 8.50 Zentalis Pharmaceuticals: Pipeline Overview
Table 8.51 Eisai Therapeutics: Company Overview
Table 8.52 Eisai Therapeutics: Pipeline Overview
Table 11.1 Patent Analysis: Top CPC Sections
Table 11.2 Patent Analysis: Top CPC Symbols
Table 11.3 Patent Analysis: Top CPC Codes
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Portfolio: List of Leading Patents (By Highest Relative Valuation)
Table 11.7 Patent Portfolio: List of Leading Patents (By Number of Citations)
Table 13.1 Targeted Protein Degradation: List of Partnerships and Collaborations
Table 13.2 Partnerships and Collaborations: Information on Type of Agreement (Country and Region)
Table 14.1 Targeted Protein Degradation: List of Funding and Investments, 2018-2024
Table 16.1 List of Targeted Protein Degradation Therapies Forecasted
Table 21.1 Targeted Protein Degradation Technologies: Average Upfront Payment and Average Milestone Payment, 2015-2024 (USD Million)
Table 21.2 Library Licensing Deal: Tranches of Milestone Payments
Table 22.1 GlycoEra: Company Snapshot
Table 22.2 Polyprox Therapeutics: Company Snapshot
Table 22.3 Xios Therapeutics: Company Snapshot
Table 22.4 Mission Therapeutics: Company Snapshot
Table 22.5 Ubiquigent: Company Snapshot
Table 22.6 Almac Discovery: Company Snapshot
Table 22.7 University of Delaware: Company Snapshot
Table 22.8 Francis Crick Institute: Company Snapshot
Table 22.9 Anonymous: Company Snapshot
Table 22.10 Anonymous: Company Snapshot
Table 24.1 Targeted Protein Degradation Therapies: Distribution by Stage of Development
Table 24.2 Targeted Protein Degradation Technologies: Distribution by Type of Degrader
Table 24.3 Targeted Protein Degradation Therapies: Distribution by Biological Target
Table 24.4 Targeted Protein Degradation Therapies: Distribution by Target Enzyme
Table 24.5 Targeted Protein Degradation Therapies: Distribution by Target Indication
Table 24.6 Targeted Protein Degradation Therapies: Distribution by Therapeutic Area
Table 24.7 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment
Table 24.8 Targeted Protein Degradation Therapy Developers: Distribution by Company Size
Table 24.9 Targeted Protein Degradation Therapy Developers: Distribution by Location of Headquarters (Region)
Table 24.10 Targeted Protein Degradation Therapy Developers: Distribution by Year of Establishment and Location of Headquarters (Region)
Table 24.11 Targeted Protein Degradation Therapy Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 24.12 Most Active Developers: Distribution by Number of Therapies and Stage of Development
Table 24.13 Targeted Protein Degradation Technologies: Distribution by Type of Degrader Developed
Table 24.14 Targeted Protein Degradation Technologies: Distribution by Protein Degradation Pathway
Table 24.15 Targeted Protein Degradation Technologies: Distribution by Site of Degraded Protein
Table 24.16 Targeted Protein Degradation Therapies: Distribution by Therapeutic Area
Table 24.17 Targeted Protein Degradation Therapies: Distribution by Discovery Step Supported
Table 24.18 Targeted Protein Degradation Technologies: Distribution by Availability of Computational Modeling Ability
Table 24.19 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment
Table 24.20 Targeted Protein Degradation Technology Providers: Distribution by Company Size
Table 24.21 Targeted Protein Degradation Technology Providers: Distribution by Location of Headquarters (Region)
Table 24.22 Targeted Protein Degradation Technology Providers: Distribution by Year of Establishment and Location of Headquarters (Region)
Table 24.23 Targeted Protein Degradation Technology Providers: Distribution by Company Size and Location of Headquarters (Region)
Table 24.24 Arvinas: Annual Revenues, FY 2019-FY 2023 (USD Million)
Table 24.25 Bristol-Myers Squibb: Annual Revenues, FY 2019-FY 2023 (USD Billion)
Table 24.26 C4 Therapeutics: Annual Revenues, FY 2019-FY 2023 (USD Million)
Table 24.27 Radius Health: Annual Revenues, FY 2019-Q1 2022 (USD Million)
Table 24.28 AstraZeneca: Annual Revenues, FY 2019-FY 2023 (USD Billion)
Table 24.29 Roche: Annual Revenues, FY 2019-FY 2023 (CHF Billion)
Table 24.30 Clinical Trial Analysis: Cumulative Year-wise Trend, 2019-2023
Table 24.31 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year, 2019-2023
Table 24.32 Clinical Trial Analysis: Distribution by Trial Phase
Table 24.33 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Table 24.34 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2019–2023
Table 24.35 Clinical Trial Analysis: Distribution by Trial Status
Table 24.36 Clinical Trial Analysis: Distribution by Patient Gender
Table 24.37 Clinical Trial Analysis: Distribution by Target Indication
Table 24.38 Clinical Trial Analysis: Distribution by Type of Trial Masking
Table 24.39 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 24.40 Clinical Trial Analysis: Distribution by Trial Purpose
Table 24.41 Clinical Trial Analysis: Distribution by Distribution by Design Allocation
Table 24.42 Leading Industry Players: Distribution by Number of Registered Trials
Table 24.43 Leading Non-Industry Players: Distribution by Number of Registered Trials
Table 24.44 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 24.45 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
Table 24.46 Grants Analysis: Cumulative Year-wise Trend, 2019-2023
Table 24.47 Grants Analysis: Cumulative Year-wise Trend of Grants by Amount Awarded (USD Million)
Table 24.48 Grants Analysis: Distribution by Funding Institute Center
Table 24.49 Grants Analysis: Distribution by Funding Institute Center and Support Period
Table 24.50 Grants Analysis: Distribution by Support Period
Table 24.51 Grants Analysis: Distribution by Type of Grant Application
Table 24.52 Grants Analysis: Distribution by Purpose of Grant Award
Table 24.53 Grants Analysis: Distribution by Activity Code (Series)
Table 24.54 Grants Analysis: Distribution by Activity Code
Table 24.55 Grants Analysis: Distribution by Study Section Involved
Table 24.56 Most Popular NIH Departments: Distribution by Number of Grants
Table 24.57 Prominent Program Officers: Distribution by Number of Grants
Table 24.58 Popular Recipient Organizations: Distribution by Number of Grants
Table 24.59 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Table 24.60 Popular Recipient Organizations: Distribution by States in the US
Table 24.61 Patent Analysis: Distribution by Type of Patent
Table 24.62 Patent Analysis: Distribution by Patent Publication Year, 2019-2023
Table 24.63 Patent Analysis: Distribution by Patent Application Year, Pre-2019-2023
Table 24.64 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2019-2023
Table 24.65 Patent Analysis: Distribution by Patent Jurisdiction
Table 24.66 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
Table 24.67 Leading Industry Players: Distribution by Number of Patents
Table 24.68 Leading Non-Industry Players: Distribution by Number of Patents
Table 24.69 Leading Patent Assignees: Distribution by Number of Patents
Table 24.70 Patent Analysis: Distribution by Patent Age
Table 24.71 Patent Analysis: Patent Valuation
Table 24.72 Publication Analysis: Distribution by Year of Publication, 2019-2023
Table 24.73 Publication Analysis: Distribution by Type of Publication
Table 24.74 Key Journals: Distribution by Number of Publications
Table 24.75 Key Journals: Distribution by Journal Impact Factor
Table 24.76 Most Active Publisher: Distribution by Number of Publications
Table 24.77 Most Active Copyright Holder: Distribution by Number of Publications
Table 24.78 Publication Analysis: Emerging Focus Area
Table 24.79 Publication Analysis: Distribution by Therapeutic Area
Table 24.80 Publication Analysis: Distribution by Geography
Table 24.81 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2016-2024
Table 24.82 Partnerships and Collaborations: Distribution by Type of Partnership
Table 24.83 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2016-2024
Table 24.84 Partnerships and Collaborations: Distribution by Type of Partner
Table 24.85 Partnerships and Collaborations: Distribution by Type of Degrader
Table 24.86 Most Active Players: Distribution by Number of Partnerships
Table 24.87 Partnerships and Collaborations: Local and International Agreements
Table 24.88 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 24.89 Funding and Investment Analysis: Cumulative Year-wise Trend, 2014-2024
Table 24.90 Funding and Investment Analysis: Distribution by Amount Invested, 2014-2024 (USD Million)
Table 24.91 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2018-2024
Table 24.92 Funding and Investments: Distribution by Type of Funding and Amount Invested (USD Million)
Table 24.93 Year wise Distribution of Amount Invested by Type of Funding, 2018-2024
Table 24.94 Funding and Investments: Distribution by Geography (Region)
Table 24.95 Funding and Investments: Distribution by Geography (Country)
Table 24.96 Most Active Players: Distribution by Number of Funding Instances
Table 24.97 Most Active Players: Distribution by Amount Raised (USD Million)
Table 24.98 Key Investors: Distribution by Number of Funding Instances
Table 24.99 Funding and Investments Summary, 2018-2023 (USD Million)
Table 24.100 Global Targeted Protein Degradation Therapies Market, Conservative, Base and Optimistic Scenario, 2024-2035 (USD Million)
Table 24.101 Targeted Protein Degradation Therapies Market: Distribution by Type of Degrader, 2024 and 2035
Table 24.102 Targeted Protein Degradation Therapies Market for SERDs: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.103 Targeted Protein Degradation Therapies Market for PROTACs: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.104 Targeted Protein Degradation Therapies Market for Molecular Glues: Forecasted Estimates, 2030-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.105 Targeted Protein Degradation Therapies Market: Distribution by Target Indication, 2024 and 2035
Table 24.106 Targeted Protein Degradation Therapies Market for Breast Cancer: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.107 Targeted Protein Degradation Therapies Market for Multiple Myeloma: Forecasted Estimates, 2030-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.108 Targeted Protein Degradation Therapies Market: Distribution by Key Geographical Regions, 2024 and 2035 (USD Million)
Table 24.109 Targeted Protein Degradation Therapies Market in North America: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.110 Targeted Protein Degradation Therapies Market in the US: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.111 Targeted Protein Degradation Therapies Market in Canada: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.112 Targeted Protein Degradation Therapies Market in Europe: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.113 Targeted Protein Degradation Therapies Market in the UK: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.114 Targeted Protein Degradation Therapies Market in Germany: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.115 Targeted Protein Degradation Therapies Market in France: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.116 Targeted Protein Degradation Therapies Market in Spain: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.117 Targeted Protein Degradation Therapies Market in Italy: Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.118 Targeted Protein Degradation Therapies Market in Asia-Pacific: Forecasted Estimates, 2026-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.119 Targeted Protein Degradation Therapies Market in China: Forecasted Estimates, 2026-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.120 Targeted Protein Degradation Therapies Market in South Korea: Forecasted Estimates, 2026-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.121 Targeted Protein Degradation Therapies Market in India: Forecasted Estimates, 2027-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.122 Targeted Protein Degradation Therapies Market in Japan: Forecasted Estimates, 2027-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.123 Targeted Protein Degradation Therapies Market in Australia: Forecasted Estimates, 2027-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.124 Targeted Protein Degradation Therapies Market in Rest of the World: Forecasted Estimates, 2026-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.125 Targeted Protein Degradation Therapies Market in Brazil: Forecasted Estimates, 2026-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.126 Targeted Protein Degradation Therapies Market in Israel: Forecasted Estimates, 2027-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.127 Targeted Protein Degradation Therapies Market: RAD1901 / Elacestrant / Orserdu Sales Forecast, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.128 Targeted Protein Degradation Therapies Market: Vepedegestrant / ARV-471 Sales Forecast, 2025-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.129 Targeted Protein Degradation Therapies Market: OP-1250 / OP-1250-301 / Palazestrant Sales Forecast, 2027-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.130 Targeted Protein Degradation Therapies Market: LY3484356 / Imlunestrant Sales Forecast, 2028-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.131 Targeted Protein Degradation Therapies Market: CC-92480 / BMS-986348 / Mezigdomide Sales Forecast, 2030-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.132 Targeted Protein Degradation Therapies Market: Camizestrant / AZD9833 Sales Forecast, 2031-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.133 Global Targeted Protein Degradation Technologies Market, Historical Trends (2018-2023), Base Scenario (USD Million)
Table 24.134 Global Targeted Protein Degradation Technologies Market, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.135 Targeted Protein Degradation Technologies Market: Distribution by Type of Payment Model Employed, 2018, 2024 and 2035 (USD Million)
Table 24.136 Targeted Protein Degradation Technologies Market for Upfront Payments, Historical Trends 2018-2023, Base Scenario (USD Million)
Table 24.137 Targeted Protein Degradation Technologies Market for Upfront Payments, Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 24.138 Targeted Protein Degradation Technologies Market for Milestone Payments, Historical Trends, 2018-2023, Base Scenario (USD Million)
Table 24.139 Targeted Protein Degradation Technologies Market for Milestone Payments, Forecasted Estimates, 2024-2035, Conservative, Base and Optimistic Scenario (USD Million)
Table 26.1 Targeted Protein Degradation: List of Funding and Investments, 2014-2027
Please reach out to our team for the details.